
    
      There is a screening period of up to 2 weeks, a treatment period of a minimum of 52 weeks and
      a maximum of approximately up to 3 years after last patient is randomized. A total of up to
      400 patients will be randomized in a 1:1 ratio to receive either open-lable Roxadustat or
      Active Control (Epoetin alfa).
    
  